Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics, Inc. has experienced a significant stock price increase, rising by 1,893.74% over the past year and 51.6% since January 1, 2026, hitting a new 52-week high on May 6, 2026. Positive Phase 2 data for NDV-01 in high-risk NMIBC, showing a 76% complete response rate at 12 months, led to a 25% jump in shares. The company completed a $160 million PIPE financing to support Phase 3 development of NDV-01. The FDA confirmed alignment on the registrational study design for NDV-01 for two separate indications. Relmada Therapeutics is scheduled to report its First Quarter 2026 financial results on May 12, 2026, and hold its 2026 Annual Meeting of Stockholders on May 27, 2026.

As a clinical-stage biotechnology company, Relmada Therapeutics, Inc. does not experience demand seasonality in the traditional sense. Its financial performance is tied to clinical development milestones, regulatory approvals, and financing activities rather than seasonal fluctuations in product demand.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system disorders, emphasizing treatments with durable efficacy, favorable safety profiles, and real-world usability. The company's major product candidates include NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a clinical candidate targeting compulsive behaviors through GABAA receptor modulation. NDV-01 is advancing into Phase 3 trials for BCG-unresponsive and adjuvant intermediate-risk NMIBC, while Sepranolone is moving towards a Phase 2 trial for Prader-Willi syndrome.

Relmada Therapeutics, Inc. is headquartered in Coral Gables, Florida, and was founded in 2004. The company is incorporated in Nevada, United States. Clinical trials for NDV-01 have been conducted in Israel, and Relmada Therapeutics has a subsidiary named Medeor, located in Tonisvorst, Germany.

Relmada Therapeutics maintains a positive brand reputation, particularly within the scientific and investment communities. Positive clinical trial data for NDV-01 has bolstered its scientific standing, and regulatory alignment with the FDA enhances its credibility. Investor confidence is reflected in the stock price increase and successful PIPE financing. Analyst coverage is largely positive, with a "Moderate Buy" consensus rating and an average price target of $12.00.

Relmada Therapeutics, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 49.23% of the company's stock, with major holders including Janus Henderson Group Plc and Squadron Capital Management LLC. Insiders own 3.37% of the company, with the largest individual shareholder being CEO Sergio Traversa. Retail investors hold 47.40% of the company.